Crispr Therapeutics falls after weak quarterly results

Crispr Therapeutics AG

05/08/2025 11:51

** U.S.-listed shares of Crispr Therapeutics CRSP.BN, CRSP.O fall 9.8% to $53.74 premarket

** Late on Monday, co posted Q2 sales of $892,000, well below analysts' est of $6.3 million - LSEG

** Co reported Q2 EPS loss of $2.40 vs est of a loss of $1.42/share - LSEG

** As of last close, stock up 51.4% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))